Editorial: metformin for portal hypertension—old dog, new tricks?
Open Access
- 8 July 2021
- journal article
- editorial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (3), 345-346
- https://doi.org/10.1111/apt.16484
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertensionAlimentary Pharmacology & Therapeutics, 2021
- A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)Trials, 2020
- Beta-blockers in cirrhosis: Evidence-based indications and limitationsJHEP Reports, 2019
- Drug repurposing: progress, challenges and recommendationsNature Reviews Drug Discovery, 2018
- Discovery and translation of a target engagement marker for AMP-activated protein kinase (AMPK)PLOS ONE, 2018
- Metformin reduces hepatic resistance and portal pressure in cirrhotic ratsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2015
- The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-studyDigestive and Liver Disease, 2014
- Functional aspects on the pathophysiology of portal hypertension in cirrhosisJournal of Hepatology, 2012
- Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled TrialGastroenterology, 2009
- Abnormalities in proximal small bowel motility in patients with cirrhosisJournal of Hepatology, 1993